Ditsatham Chagkrit, Chitapanarux Imjai, Somwangprasert Areewan, Watcharachan Kirati, Wongmaneerung Panchaporn, Charoentum Chaiyut, Chewaskulyong Busyamas, Chakrabandhu Somvilai, Onchan Wimrak, Teeyasuntranonn Anongnart, Sripan Patumrat
Division of Head Neck Breast Surgery.
Division of Radiation Oncology,
Onco Targets Ther. 2018 Jul 31;11:4443-4447. doi: 10.2147/OTT.S166399. eCollection 2018.
We report the safety and efficacy of eribulin as a late treatment line in Thai metastatic breast cancer (MBC) patients.
A total of 30 MBC patients treated with eribulin between January 2014 and January 2017 were retrospectively analyzed. The patients were scheduled to receive 1.4 mg/m of eribulin on day 1, day 8 and subsequently every 21 days. All patients had previously received at least three chemotherapy regimens including anthracycline and taxane. Response rate and progression-free survival (PFS) were analyzed.
The median age was 56 years (range, 40-74 years), with a median follow-up time of 5.7 months (range, 0.2-25 months). The overall response rate was 30% (nine patients): four patients had triple-negative breast cancer, three patients had luminal B breast cancer and two patients had luminal A breast cancer. The median PFS was 2.9 months (range, 0.2-14 months). The median number of previous chemotherapy regimens was 4 (range, 3-9). Univariate analysis showed that the number of regimens (four or fewer) prior to eribulin was statistically associated with superior PFS ( = 0.009). Multivariate analysis also showed similar statistical association between number of prior regimens (four or fewer) and better PFS adjusted by age group (≥50 years; hazard ratio = 1.29; 95% CI: 1.0-1.65; = 0.046). There were no toxic deaths or grade 4 toxicities. Nine (30%) patients had grade 3 anemia toxicities, and the other common toxicities were leukopenia and neutropenia. Four (13%) patients required dose reduction and 16 (53%) patients required dose delay because of toxicities.
Eribulin is an effective drug for heavily pretreated MBC patients with tolerable toxicities. The benefit was superior in patients who received fewer than four previous chemotherapy regimens.
我们报告了艾日布林作为泰国转移性乳腺癌（MBC）患者晚期治疗方案的安全性和有效性。
回顾性分析了2014年1月至2017年1月期间接受艾日布林治疗的30例MBC患者。患者计划在第1天、第8天接受1.4mg/m²的艾日布林治疗，随后每21天给药一次。所有患者此前至少接受过三种化疗方案，包括蒽环类和紫杉烷类。分析了缓解率和无进展生存期（PFS）。
中位年龄为56岁（范围40 - 74岁），中位随访时间为5.7个月（范围0.2 - 25个月）。总缓解率为30%（9例患者）：4例患者为三阴性乳腺癌，3例患者为管腔B型乳腺癌，2例患者为管腔A型乳腺癌。中位PFS为2.9个月（范围0.2 - 14个月）。既往化疗方案的中位数量为4个（范围3 - 9个）。单因素分析显示，艾日布林治疗前的化疗方案数量（4个或更少）与更好的PFS在统计学上相关（P = 0.009）。多因素分析还显示，既往化疗方案数量（4个或更少）与按年龄组（≥50岁）调整后的更好的PFS之间存在相似的统计学关联（风险比 = 1.29；95%置信区间：1.0 - 1.65；P = 0.046）。没有出现毒性死亡或4级毒性反应。9例（30%）患者出现3级贫血毒性反应，其他常见毒性反应为白细胞减少和中性粒细胞减少。4例（13%）患者需要减量，16例（53%）患者因毒性反应需要延迟给药。
艾日布林是一种对经过大量治疗的MBC患者有效的药物，毒性可耐受。对于既往接受化疗方案少于4个的患者，获益更大。
